Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer

D. Kay Blanchard, John H. Donohue, Carol Reynolds, Clive S. Grant, Kelly McMasters, Jose M. Velasco, David Winchester, David S. Robinson, James E Goodnight Jr, Claude H. Organ

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Hypothesis: Axillary relapse in node-negative patients staged with sentinel lymph node (SLN) biopsy alone is no more frequent than in patients treated with standard axillary dissection. Morbidity is less for patients who had SLN biopsy, Design, Setting, and Patients: Between October 14, 1997, and August 31, 2001, 1253 consecutive women with primary invasive breast cancer were prospectively entered into an SLN biopsy database. Completion axillary dissection was performed in 164 patients after SLN biopsy as part of a training protocol. Interventions: Patients were contacted by questionnaire or telephone to determine breast cancer relapse; presence of arm lymphedema, arm pain, axillary infection, or seroma formation; and tumor recurrence or death. Main Outcome Measures: χ2 or Fisher exact tests and Wilcoxon rank sum tests were used to analyze categorical and continuous variables. Logistic regression was used to analyze morbidity. Results: Of 1253 women, 894 (71%) were node negative by SLN biopsy alone (n=730 [82%]) or SLN biopsy and completion axillary dissection (n = 164 [18%]). Questionnaires were completed by 776 patients (87%). Mean±SD follow-up was 2.4±0.9 years. Patients with axillary dissections reported a significantly higher occurrence of arm lymphedema (34%), arm pain (38%), seroma formation (24%), and infection (9%) vs SLN biopsyonly patients (6%, 14%, 7%, and 3%, respectively). One axillary relapse (0.1%) occurred during follow-up of 685 women who underwent SLN biopsy only. Conclusions: With intermediate-term follow-up, there was 1 axillary recurrence in 685 SLN node-negative women, supporting use of SLN biopsy as an accurate method for staging breast cancer. Biopsy of the SLN was associated with significantly less morbidity than completion axillary dissection.

Original languageEnglish (US)
Pages (from-to)482-488
Number of pages7
JournalArchives of Surgery
Volume138
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Sentinel Lymph Node Biopsy
Dissection
Breast Neoplasms
Morbidity
Recurrence
Seroma
Lymphedema
Nonparametric Statistics
Pain
Infection
Telephone
Logistic Models
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Surgery

Cite this

Blanchard, D. K., Donohue, J. H., Reynolds, C., Grant, C. S., McMasters, K., Velasco, J. M., ... Organ, C. H. (2003). Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Archives of Surgery, 138(5), 482-488. https://doi.org/10.1001/archsurg.138.5.482

Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. / Blanchard, D. Kay; Donohue, John H.; Reynolds, Carol; Grant, Clive S.; McMasters, Kelly; Velasco, Jose M.; Winchester, David; Robinson, David S.; Goodnight Jr, James E; Organ, Claude H.

In: Archives of Surgery, Vol. 138, No. 5, 01.05.2003, p. 482-488.

Research output: Contribution to journalArticle

Blanchard, DK, Donohue, JH, Reynolds, C, Grant, CS, McMasters, K, Velasco, JM, Winchester, D, Robinson, DS, Goodnight Jr, JE & Organ, CH 2003, 'Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer', Archives of Surgery, vol. 138, no. 5, pp. 482-488. https://doi.org/10.1001/archsurg.138.5.482
Blanchard, D. Kay ; Donohue, John H. ; Reynolds, Carol ; Grant, Clive S. ; McMasters, Kelly ; Velasco, Jose M. ; Winchester, David ; Robinson, David S. ; Goodnight Jr, James E ; Organ, Claude H. / Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. In: Archives of Surgery. 2003 ; Vol. 138, No. 5. pp. 482-488.
@article{5ac1f45b130448249b8b4ce197daffe8,
title = "Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer",
abstract = "Hypothesis: Axillary relapse in node-negative patients staged with sentinel lymph node (SLN) biopsy alone is no more frequent than in patients treated with standard axillary dissection. Morbidity is less for patients who had SLN biopsy, Design, Setting, and Patients: Between October 14, 1997, and August 31, 2001, 1253 consecutive women with primary invasive breast cancer were prospectively entered into an SLN biopsy database. Completion axillary dissection was performed in 164 patients after SLN biopsy as part of a training protocol. Interventions: Patients were contacted by questionnaire or telephone to determine breast cancer relapse; presence of arm lymphedema, arm pain, axillary infection, or seroma formation; and tumor recurrence or death. Main Outcome Measures: χ2 or Fisher exact tests and Wilcoxon rank sum tests were used to analyze categorical and continuous variables. Logistic regression was used to analyze morbidity. Results: Of 1253 women, 894 (71{\%}) were node negative by SLN biopsy alone (n=730 [82{\%}]) or SLN biopsy and completion axillary dissection (n = 164 [18{\%}]). Questionnaires were completed by 776 patients (87{\%}). Mean±SD follow-up was 2.4±0.9 years. Patients with axillary dissections reported a significantly higher occurrence of arm lymphedema (34{\%}), arm pain (38{\%}), seroma formation (24{\%}), and infection (9{\%}) vs SLN biopsyonly patients (6{\%}, 14{\%}, 7{\%}, and 3{\%}, respectively). One axillary relapse (0.1{\%}) occurred during follow-up of 685 women who underwent SLN biopsy only. Conclusions: With intermediate-term follow-up, there was 1 axillary recurrence in 685 SLN node-negative women, supporting use of SLN biopsy as an accurate method for staging breast cancer. Biopsy of the SLN was associated with significantly less morbidity than completion axillary dissection.",
author = "Blanchard, {D. Kay} and Donohue, {John H.} and Carol Reynolds and Grant, {Clive S.} and Kelly McMasters and Velasco, {Jose M.} and David Winchester and Robinson, {David S.} and {Goodnight Jr}, {James E} and Organ, {Claude H.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1001/archsurg.138.5.482",
language = "English (US)",
volume = "138",
pages = "482--488",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer

AU - Blanchard, D. Kay

AU - Donohue, John H.

AU - Reynolds, Carol

AU - Grant, Clive S.

AU - McMasters, Kelly

AU - Velasco, Jose M.

AU - Winchester, David

AU - Robinson, David S.

AU - Goodnight Jr, James E

AU - Organ, Claude H.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Hypothesis: Axillary relapse in node-negative patients staged with sentinel lymph node (SLN) biopsy alone is no more frequent than in patients treated with standard axillary dissection. Morbidity is less for patients who had SLN biopsy, Design, Setting, and Patients: Between October 14, 1997, and August 31, 2001, 1253 consecutive women with primary invasive breast cancer were prospectively entered into an SLN biopsy database. Completion axillary dissection was performed in 164 patients after SLN biopsy as part of a training protocol. Interventions: Patients were contacted by questionnaire or telephone to determine breast cancer relapse; presence of arm lymphedema, arm pain, axillary infection, or seroma formation; and tumor recurrence or death. Main Outcome Measures: χ2 or Fisher exact tests and Wilcoxon rank sum tests were used to analyze categorical and continuous variables. Logistic regression was used to analyze morbidity. Results: Of 1253 women, 894 (71%) were node negative by SLN biopsy alone (n=730 [82%]) or SLN biopsy and completion axillary dissection (n = 164 [18%]). Questionnaires were completed by 776 patients (87%). Mean±SD follow-up was 2.4±0.9 years. Patients with axillary dissections reported a significantly higher occurrence of arm lymphedema (34%), arm pain (38%), seroma formation (24%), and infection (9%) vs SLN biopsyonly patients (6%, 14%, 7%, and 3%, respectively). One axillary relapse (0.1%) occurred during follow-up of 685 women who underwent SLN biopsy only. Conclusions: With intermediate-term follow-up, there was 1 axillary recurrence in 685 SLN node-negative women, supporting use of SLN biopsy as an accurate method for staging breast cancer. Biopsy of the SLN was associated with significantly less morbidity than completion axillary dissection.

AB - Hypothesis: Axillary relapse in node-negative patients staged with sentinel lymph node (SLN) biopsy alone is no more frequent than in patients treated with standard axillary dissection. Morbidity is less for patients who had SLN biopsy, Design, Setting, and Patients: Between October 14, 1997, and August 31, 2001, 1253 consecutive women with primary invasive breast cancer were prospectively entered into an SLN biopsy database. Completion axillary dissection was performed in 164 patients after SLN biopsy as part of a training protocol. Interventions: Patients were contacted by questionnaire or telephone to determine breast cancer relapse; presence of arm lymphedema, arm pain, axillary infection, or seroma formation; and tumor recurrence or death. Main Outcome Measures: χ2 or Fisher exact tests and Wilcoxon rank sum tests were used to analyze categorical and continuous variables. Logistic regression was used to analyze morbidity. Results: Of 1253 women, 894 (71%) were node negative by SLN biopsy alone (n=730 [82%]) or SLN biopsy and completion axillary dissection (n = 164 [18%]). Questionnaires were completed by 776 patients (87%). Mean±SD follow-up was 2.4±0.9 years. Patients with axillary dissections reported a significantly higher occurrence of arm lymphedema (34%), arm pain (38%), seroma formation (24%), and infection (9%) vs SLN biopsyonly patients (6%, 14%, 7%, and 3%, respectively). One axillary relapse (0.1%) occurred during follow-up of 685 women who underwent SLN biopsy only. Conclusions: With intermediate-term follow-up, there was 1 axillary recurrence in 685 SLN node-negative women, supporting use of SLN biopsy as an accurate method for staging breast cancer. Biopsy of the SLN was associated with significantly less morbidity than completion axillary dissection.

UR - http://www.scopus.com/inward/record.url?scp=0038709383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038709383&partnerID=8YFLogxK

U2 - 10.1001/archsurg.138.5.482

DO - 10.1001/archsurg.138.5.482

M3 - Article

C2 - 12742949

AN - SCOPUS:0038709383

VL - 138

SP - 482

EP - 488

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 5

ER -